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J Vet Diagn Invest 16:101–107 (2004)
Erysipelothrix rhusiopathiae: genetic characterization of midwest
US isolates and live commercial vaccines using pulsed-field
gel electrophoresis
T. Opriessnig, L. J. Hoffman, D. L. Harris, S. B. Gaul, P. G. Halbur1
Abstract. This is the first report of molecular characterization of US erysipelas field isolates and vaccine
strains of Erysipelothrix rhusiopathiae by pulsed-field gel electrophoresis (PFGE). Erysipelas in pigs is mainly
caused by E. rhusiopathiae serotypes 1a, 1b, and 2. In 2001, erysipelas reemerged as a clinical problem in pigs
in the midwestern United States. In this work 90 erysipelas isolates (58 recent and 28 archived field isolates
as well as 4 live-vaccine strains) were genetically characterized. Because of the limited availability of antiserum,
74/90 isolates (44/58 recent isolates) were serotyped. The serotype of the majority (79.6%) of the 44 recent
isolates tested was determined to be 1a, 13.6% were serotype 1b, and 6.8% of recent isolates were serologically
untypeable. Among all 90 isolates, 23 different PFGE patterns were identified. There were 43 isolates identified
as serotype 1a with 4 genetic patterns: 38/43, 1A(I); 3/43, 1A(III); 1/43, 1B(V); and 1/43, 3B. Sixteen serotype
1b isolates had 11 unique genetic patterns: 4/16 were genotype 1B(III), 2/16 were genotype 3A(I), and 1/16
was in genotype groups 1A(V), 1A(VI), 1A(VII), 1B(I), 1B(IV), 1B(VII), 2, 4, and 5. Six genetic patterns were
distinguished among the 10 serotype 2 isolates: 1A(IV) (1/10), 1A(V) (1/10), 1B(VI) (1/10), 2 (4/10), 7 (1/10),
and 8 (2/8). Erysipelas vaccine strains (modified live) were similar to each other but different from current field
strains, sharing 78.6% identity with the most prevalent genotype 1A(I) based on the PFGE-SmaI pattern. Com-
pared with serotyping, PFGE genotyping is a more distinguishing technique, easy to perform and not dependent
on the limited availability of antiserum.
In the United States, during the summer of 2001,
erysipelas began occurring with increasing frequency
in both vaccinated and nonvaccinated pigs. The clini-
cal picture was typically acute at onset, with mortality
attributed primarily to sudden deaths among pigs in
the late stages of the grow–finish period. A 9-year
analysis from cases submitted to the Iowa State Uni-
versity Veterinary Diagnostic Laboratory, Ames, IA
(ISU-VDL) demonstrated a 4-fold increase of erysip-
elas cases in 2001 compared with the years 1993–
2000. There has also been a marked increase in carcass
condemnations associated with erysipelas-like skin le-
sions for several months after the outbreaks, with a
peak of 4,000 condemnations per million carcasses in
August 2001 (M. Engle, personal communication).
Practitioners and producers have raised questions on
the emergence of new Erysipelothrix rhusiopathiae se-
rotypes or strains, vaccine efficacy, and safety of live
erysipelas vaccines.
The gram-positive, facultative anaerobic bacterium
E. rhusiopathiae is widely distributed and causes ery-
sipelas in swine, sheep, fish, reptiles, and birds, as well
From the Departments of Veterinary Diagnostic and Production
Animal Medicine (Opriessnig, Hoffman, Harris, Halbur), and Mi-
crobiology (Harris, Gaul), Iowa State University, Ames, IA 50011.
1Corresponding Author: P. G. Halbur, Department of Veterinary
Diagnostic and Production Animal Medicine, College of Veterinary
Medicine, Iowa State University, Ames, IA 50011.
as erysipeloid, a human skin disease.13 The genus Er-
ysipelothrix is divided into the species E. rhusiopa-
thiae (serovars 1a, 1b, 2, 4, 5, 6, 8, 9, 11, 12, 15, 16,
17, 19, 21, and N), E. tonsillarum (serovars 3, 7, 10,
14, 20, 22, and 23), Erysipelothrix sp. strain 1 (serovar
13), and E. sp. strain 2 (serovar 18). This distinction
was made based on DNA–DNA hybridization and
with polymerase chain reaction.8,9,11 The pig is known
to be susceptible to at least 15 of the 28 described
serotypes (Enoi C, Norrung V: 1992, Proc Int Pig Vet
Soc: 345). Serotype 1a and 1b are associated with
acute erysipelas, whereas serotype 2 is often associated
with the chronic form of the disease (Yong-Jian S, Wei
H: 1990, Proc Int Pig Vet Soc: 193).
Thirty-to-fifty percent of pigs are known to harbor
E. rhusiopathiae.13 Usually, these pigs are healthy, yet
the organism can be found in tonsils and lymphoid
tissues. Subclinically infected pigs are thought to be
the reservoir for acute erysipelas outbreaks. Erysipe-
lothrix rhusiopathiae is shed in feces, urine, saliva, and
nasal secretions. Generally, the most susceptible hosts
are pigs between 3 months and 3 years of age. Pigs
less than 3 months of age seem to be protected by
maternal antibodies, and pigs over 3 years have ac-
quired protective immunity by going through multiple
subclinical infections during their life.13
Recently it has been demonstrated that pulsed-field
gel electrophoresis (PFGE) can be used to differentiate
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Table 1. Differences in antibiotic susceptibility among erysipelas vaccine strains.
Vaccine strain Florfenicol Oxytetracycline Trimethoprim
Suvaxynw E-oral‡
ERY VAC 100†
Erycelly*
Ingelvacw ERY-ALC§
intermediate
intermediate
susceptible
intermediate
susceptible
susceptible
susceptible
resistant
resistant
susceptible
resistant
resistant
* Novartis Animal Vaccines, Inc.
† Arko Laboratories Limited.
‡ Fort Dodge Animal Health, Inc.
§ Boehringer Ingelheim Vetmedica, Inc.
Table 2. Pulsed-field gel electrophoresis patterns (genotypes) of recent and archived serotype 1a field isolates.
Isolate No. Date isolated Genotype Isolate No. Date isolated Genotype
HC-585
ME-7
2437
2449
2403
2329
2336
EI-6P
Feb 12, 1975*
Feb 10, 1976*
Apr 26, 1977*
Apr 26, 1977*
Apr 26, 1977*
Apr 26, 1977*
Apr 26, 1977*
Apr 14, 1983*
1B(V)
1A(III)
1A(I)
1A(I)
1A(I)
1A(I)
1A(I)
3B
48251/01
48554/01
49313/01
5024/01
51172/01
51675/01
53225/E/01
53815/01
Aug 27, 2001
Aug 28, 2001
Aug 30, 2001
Jan 23, 2001
Sep 11, 2001
Sep 14, 2001
Sep 24, 2001
Sep 26, 2001
1A(I)
1A(I)
1A(I)
1A(III)
1A(I)
1A(III)
1A(I)
1A(I)
34930/99
35050/01
37187/01
37472/01
40088/01
40127/01
41721/01
41878/01
Oct 4, 1999
Jun 26, 2001
Jul 3, 2001
Jul 12, 2001
Jul 17, 2001
Jul 17, 2001
Jul 24, 2001
Jul 30, 2001
1A(I)
1A(I)
1A(I)
1A(I)
1A(I)
1A(I)
1A(I)
1A(I)
55600/01
57146/01
57592/01
58689/01
59086/01
59172/01
60716/01
60785/01
Oct 8, 2001
Oct 16, 2001
Oct 19, 2001
Oct 25, 2001
Oct 30, 2001
Oct 30, 2001
Nov 8, 2001
Nov 8, 2001
1A(I)
1A(I)
1A(I)
1A(I)
1A(I)
1A(I)
1A(I)
1A(I)
44890/01
45408/01
45875/01
45879/01
47418/01
48236/01
Aug 8, 2001
Aug 10, 2001
Aug 21, 2001
Aug 14, 2001
Aug 22, 2001
Aug 25, 2001
1A(I)
1A(I)
1A(I)
1A(I)
1A(I)
1A(I)
62490/01
64765/01
65403/01
65408/01
67002/01
Nov 20, 2001
Dec 4, 2001
Dec 7, 2001
Dec 7, 2001
Dec 15, 2001
1A(I)
1A(I)
1A(I)
1A(I)
1A(I)
* Date lyophilized.
strains of Erysipelopathiae within a serotype.5 The ob-
jectives of this study were to adapt and shorten the
PFGE technique for use in a diagnostic laboratory, to
use the PFGE for differentiation of genotypes within
a serotype, and to compare recent erysipelas field iso-
lates with vaccine strains and field strains from pre-
vious outbreaks in the United States. Comparison of
field isolates with vaccine strains should help deter-
mine whether the outbreaks are due to differences in
genotype and a lack of heterologous protection and
whether the live vaccines themselves may be respon-
sible for some of the erysipelas outbreaks.
Materials and methods
Sample source. Fifty-eight recent erysipelas field isolates re-
covered from tissues and animals submitted to the ISU-VDL
during the years 1999–2002 were evaluated in this study. In
addition, 5 attenuated live-vaccine strains of E. rhusiopathiae
(Ingelvact ERY-ALC,a Erycelly,b Suvaxynt E-oral,c and ERY
VAC 100d) and several archived E. rhusiopathiae isolates of
known serotypes (10 serotype 2 isolates [1946–1988], 10 se-
rotype 1b isolates [1948–1999], and 8 serotype 1a isolates
[1975–1983]) were genetically compared with the recent field
isolates. The recent field isolates had been collected and main-
tained at 280 C in PPLO medium (b-nicotinamide adenine
dinucleotide,e BBLt Mycoplasma broth base,f horse serumg)
until further examination. All archived isolates had been stored
lyophilized in sealed glass tubes.
Culture and antibiogram. Each isolate was cultured on
5% sheep blood agar and incubated at 37 C for 48 hr. After
incubation the cultures were evaluated for purity. Antibio-
grams of all isolates were conducted according to a stan-
dardized protocol,4 using the National Committee for Clini-
cal Laboratory Standards (NCCLS) microdilution technique.
Susceptibility to the following antibiotics was tested: ampi-
cillin, apramycin, ceftiofur, chlortetracycline, clindamycin,
enrofloxacin, erythromycin, florfenicol, gentamicin, neomy-
cin, oxytetracycline, penicillin, sulfachlorpyridazine, sulfad-
imethoxine, sulfathiazole, tiamulin, tilmicosin, trimethoprim,
and tylosin. Quality control was performed with Escherichia
coli, Pseudomonas aeruginosa, Enterococcus faecalis, and
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Table 3. Pulsed-field gel electrophoresis patterns (genotype) of
serotype 1b isolates and the 2 modified live-vaccine strains.
Isolate No. Date isolated Genotype
228 H
F-45
HC2900
422-1
De Castro
EW2
DG 1534
OARDC 3
OARDC 4
Oct 26, 1948*
May 2, 1950*
Jun 21, 1950*
Feb 16, 1961*
Jul 13, 1962*
Apr 24, 1974*
Jun 5, 1979*
Jan 31, 1980*
Nov 20, 1980*
1A(VII)
1B(III)
1B(III)
1B(IV)
2
1B(I)
1A(V)
1B(III)
1B(III)
DG1966 HT
35078/00
18850/01
22524/01
57586/01
57742/01
58262/01
ERY VAC 100†
Ingelvacw ERY-ALC‡
Jun 5, 1999*
Jul 28, 2000
Apr 4, 2001
Apr 25, 2001
Oct 19, 2001
Oct 19, 2001
Oct 24, 2001
. . .
. . .
4
3A(I)
Undetected
5
1B(VII)
3A(I)
1A(VI)
1A(II)
1A(II)
* Date lyophilized.
† Arko Laboratories Limited.
‡ Boehringer Ingelheim Vetmedica, Inc.
Table 4. Pulsed-field gel electrophoresis patterns (genotype) of
serotype 2 isolates.
Isolate No. Date isolated Genotype
US 35
8943
R-32
CN3461
M-3
830
NF-4
CN3342
SE-9
Jena 36
Nov 8, 1949*
Nov 10, 1971*
Jan 24, 1973*
Apr 12, 1979*
Dec 18, 1946*
Aug 16, 1949*
Aug 22, 1972*
Apr 19, 1979*
Nov 8, 1983*
Feb 24, 1988*
1B(VI)
1A(IV)
2
2
8
7
8
2
2
1A(V)
* Date lyophilized.
Staphylococcus aureus. For inoculation the technical details
of the veterinary NCCLS documents4 were followed. All re-
sults were within the limits established by NCCLS.4
Serotyping. A single colony was picked and inoculated
into 60 ml of heart infusion brothf with horse serumg and
incubated overnight at 37 C. Cells were then killed by ad-
dition of 1% formalin,e held at room temperature overnight,
harvested 1 day later by centrifugation, and washed twice in
saline. After this step the cells were resuspended in 1.5 ml
formalized salinee and autoclaved for 1 hr at 100 C.15 The
supernatant obtained from this step was collected and used
as antigen in a gel precipitation test.2 Homologous positive
controls were used with each test. Reactions were recorded
after 24 hr.15 Erysipelothrix rhusiopathiae isolates were se-
rotyped at the National Veterinary Services Laboratories
(NVSL), Ames, Iowa.
DNA preparation. The bacteria were picked with a swab
and suspended in a cell suspension buffer (100 mM Tris–HCl,
100 mM ethylenediaminetetraacetic acid [EDTA] [pH 8.0]) to
an absorbance of 1.0–1.1 in a spectrophotometer set at a
wavelength of 612 nm. Ten microliters of lysozymee in a final
concentration of 58.1 U/gml were added to 400 ml of the
bacterial suspension and incubated for 30 min at 37 C. After
incubation the plugs were prepared by adding 90 ml mutan-
olysin (5 U/gml),e 20 ml proteinase K (20 mg/ml),g and 400
ml melt plug agar.h The solidified plugs were placed in cell
lysis buffer (50 mM Tris–HCl, 50 mM EDTA [pH 8.0], 1%
sarcosyle) and 40 ml proteinase K (20 mg/ml)g in a shaking
water bath at 54 C for 1.5 hr. After washing with autoclaved
water and TE buffer (10 mM Tris–HCl, 1 mM EDTA [pH
8.0]), the plugs were stored in TE buffer at 4 C until use.
Pulsed-field gel electrophoresis. Digestion was done with
SmaIi at a working concentration of 2.5%, with 1% bovine
serum albumini and 10% buffer,i at 37 C for 2 hr. The di-
gested plugs were loaded in their appropriate wells in the
gel (pulsed-field certified agaroseh). Electrophoresis was car-
ried out in a contour-clamped homogeneous electric field
(CHEF DRIIIh) for 21 hr at 12 C and 6 V with pulse times
from an initial 2.2 sec to a final 64 sec. Pulsed-field gel
electrophoresis patterns were detected by UV transillumi-
nation after ethidium bromide staining. Lambda ladderh was
used as DNA size standard.
Data analysis. Pulsed-field gel electrophoresis patterns
were analyzed visually and also compared with BioNumerics
software. Dendograms used the unweighted pair group meth-
od using arithmetic averages (UPGMA), dice coefficient,
and 0.9% optimization with 2.0% band position tolerance.3
Results
Culture and antibiogram. Colonies from all the ery-
sipelas field isolates and the vaccine strains were sim-
ilar. They appeared tiny and were transparent, rough-
to-smooth colonies with a narrow zone of partial he-
molysis in some of the isolates. Antibiograms showed
that all isolates were susceptible to ampicillin, ceftiof-
ur, clindamycin, enrofloxacin, erythromycin, penicil-
lin, tiamulin, tilmicosin, and tylosin, whereas all iso-
lates were resistant to apramycin, neomycin, sulfadi-
methoxine, sulfachlorpyridazine, and sulfathiazole.
Differences in susceptibility among isolates were
found with the following antibiotics: chlortetracycline
(32/90 resistant, 20/90 intermediate, 38/60 suscepti-
ble), florfenicol (1/90 resistant, 62/90 intermediate, 27/
60 susceptible), gentamicin (86/90 resistant, 2/90 in-
termediate, 2/60 susceptible), oxytetracycline (33/90
resistant, 18/90 intermediate, 39/60 susceptible), and
trimethoprim (46/90 resistant, 44/60 susceptible). The
susceptibility profiles seemed to follow no specific pat-
tern and were independent of serotype or genotype.
The vaccine strains showed differences among them
with 3/19 antibiotics tested (Table 1).
Serotyping. Because of a lack of antiserum, only
44/58 recent isolates from 1999 to 2001 were sero-
typed. Thirty-five of the isolates from the years 1999
to 2001 were serotype 1a (Table 2). One isolate from
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Table 5. Pulsed-field gel electrophoresis patterns (genotype) of field isolates not tested because of unavailability of antiserum.
I s o l a t e
No. Date isolated Genotype Isolate No. Date isolated Genotype
37289/00
44997/00
60682/01
23581/02
26914/02
Aug 9, 2000
Sep 22, 2000
Nov 7, 2001
May 10, 2002
Jun 3, 2002
1A(I)
1B(II)
6
1A(I)
1A(I)
37198/02
37200/02
38051/02
38915/02
40281/02
Jul 23, 2002
Jul 23, 2002
Jul 26, 2002
Jul 31, 2002
Aug 7, 2002
1A(I)
1A(I)
1A(I)
1A(I)
1A(I)
33644/02
33882/02
35030/02
35091/02
36232/02
Jul 8, 2002
Jul 9, 2002
Jul 12, 2002
Jul 12, 2002
Jul 18, 2002
1A(I)
1A(I)
1A(I)
1A(I)
1A(I)
26070/02
30498/02
Suvaxynw E-oral*
Erycelly†
May 20, 2002
Jun 21, 2002
. . .
. . .
3A(I)
3A(II)
1A(II)
1A(II)
* Fort Dodge Animal Health, Inc.
† Novartis Animal Vaccines, Inc.
Figure 1. Pulsed-field gel electrophoresis gel showing 12 erysipelas field isolates (lanes 1–12) digested with SmaI. A 48.5-kb lambda
DNA size standard (lane M), genotype 1A(I) isolates (lanes 1, 2, 5, 6, 8, and 9), genotype 1B(VII) isolate (lane 3), genotype 1A(III) isolate
(lane 4), genotype 1B(II) isolate (lane 7), genotype 1B(I) isolate (lane 10), genotype 1A(II) isolate (lane 11), and genotype 1B(VI) isolate
(lane 12).
2000 and 5 isolates from 2001 were serotype 1b (Table
3). The serotype could not be determined for two 2000
isolates and one 2001 isolate (Table 5).
Pulsed-field gel electrophoresis and data analysis.
Pulsed-field gel electrophoresis patterns after restric-
tion with SmaI were characterized by 8–14 bands in a
24.3–388-kb size range (Fig. 1). With PFGE it was
possible to distinguish 23 different patterns from the
90 E. rhusiopathiae isolates (Tables 2–5; Fig. 2). Ge-
netic labeling was done after comparison of the genetic
relationships among the isolates. Dendogram analysis
revealed that at 30% divergence, 8 PFGE groups (A–
H) were present (Fig. 2). At 27% divergence, groups
A and C were divided into subgroups A1/A2 and C1/
C2, respectively. Within the dendogram the serotypes
followed no specific pattern and were distributed
throughout. The majority of the isolates (63/90) were
within subgroup A1. Fifty-one of these isolates (38
serotype 1a, 12 not serotyped, 1 serotype undetected)
belonged to genotype 1A(I). Erysipelas live vaccines
were slightly different from genotype 1A(I) but were
identical to each other. They were designated as ge-
notype 1A(II). Data analysis of the homogeneity of the
PFGE patterns among the 1A genotypes revealed that
1A(I) and 1A(II) were 78.6% identical, 1A(I) and
1A(III) shared 91.7% identity, and the PFGE-patterns
of 1A(II) and 1A(III) were 85.7% identical. Archived
isolate 1A(IV) had the highest homology (92.9%) with
the vaccine strains.
Discussion
This study represents the first genetic analysis of
United States field isolates of E. rhusiopathiae. Diag-
nosis of erysipelas is typically confirmed by culture of
the causative agent, and on rare occasions the isolates
are serotyped. This service is offered only at the
NVSL and has been temporarily terminated because of
limited amounts of antiserum. Although most of the
isolates are serotype 1a or 1b, it has not been possible
in the past to genetically characterize strains within a
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Figure 2. Genetic relationship between 32 erysipelas field isolates and 4 vaccine strains and schematic representation of 23 different
PFGE patterns obtained after restriction with SmaI. The classification and divergence of isolates were calculated by the unweighted pair
group method with averages from the PFGE results. At 30% divergence, 8 PFGE groups (A–H) were present; 2 of these groups, A and
C, were subgrouped into A1/A2 and C1/C2 at 27% divergence, respectively.
given serotype. A recently published PFGE technolo-
gy5 was modified for completion in 2 days rather than
5 days. Pulsed-field gel electrophoresis on recent se-
rotype 1a isolates resulted in 2 patterns among 35 iso-
lates. Thirty-three isolates were determined to be ge-
notype 1A(I), and 2 isolates were designated as
1A(III). Among 6 recent serotype 1b isolates, 4 dif-
ferent patterns were identified. Two isolates were de-
termined to be genotype 3A(I), and 1 isolate each was
designated to be genotypes 1A(VI), 1B(VII), and 5.
The pattern of 1 serotype 1b isolate remained unde-
tected. It was found that the PFGE technique allowed
for a reproducible determination of genotype, with the
possibility of inferring serotype from such data, es-
pecially when identifying genotypes 1A(I), 1A(III),
and 3A(I), which currently seem to be the most com-
mon genotypes in the field.
By using PFGE, it was possible to compare recent
isolates with archived ones. Because of availability of
only a few older isolates in the archives, limited conclu-
sions can be drawn in terms of whether genotype chang-
es have occurred over time. Among 28 archived isolates,
5 archived 1a isolates were identified as genotype 1A(I),
which was the major genotype among the 1999–2002
isolates. Also, genotype 1A(III) was found in an isolate
from 1976, and it reappeared in 2 field isolates recovered
in 2001. These findings disprove speculations over the
appearance of new strains accounting for current out-
breaks. The remaining 3 archived 1a isolates had unique
patterns not observed in any of the recent field isolates.
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This was also the case for archived serotype 1b isolates,
which seemed not to share genetic profiles with recent
isolates based on PFGE.
In addition to PFGE, all isolates were tested for sus-
ceptibility to antibiotics for additional evidence on re-
lationships of the isolates, as is commonly done with
Salmonella sp.6 The current resistance analysis showed
that all isolates were susceptible to a variety of anti-
biotics and also resistant to others. The resistance or
susceptibility of erysipelas to 14 antibiotics appeared
to be stable over time because the oldest isolate was
lyophilized in 1948. Differences in susceptibility were
found in only 5 antibiotics (chlortetracycline, florfen-
icol, gentamicin, oxytetracycline, and trimethoprim).
Susceptibility to these antibiotics appeared arbitrary
and did not seem to follow a specific pattern in terms
of serotypes or genotypes, or time recovered.
After analysis of 90 E. rhusiopathiae isolates, the
question remains why a significant increase of erysip-
elas cases occurred in Iowa during 2001–2002. Vac-
cines have been available for prevention of clinical
erysipelas since 1947, and there are at least 4 modified
live vaccines and 12 killed bacterins currently avail-
able in the United States. Prevention through vacci-
nation is usually effective, and challenge studies per-
formed on vaccinated pigs with vaccines containing
serotype 2 demonstrated protection from acute erysip-
elas caused by serotypes 1 and 2.10,12,14 Thus far, the
authors have not been able to obtain strains of E. rhu-
siopathiae that were used to prepare inactivated vac-
cines. Two of the live-vaccine strains were serotype 1,
whereas the other 2 had to remain untested because of
the unavailability of antisera. The genotyping of all 4
live-vaccine strains indicated the same 1A(II)-PFGE
pattern, suggesting that they are the same strain. The
majority of the recent isolates submitted to the ISU-
VDL were genotype 1A(I), and all the genotype 1A(I)
isolates serotyped were serotype 1a.
Among the current cases, 8 outbreaks were reported
in herds using an erysipelas vaccination program.
There were no reports regarding erysipelas vaccination
in the other cases. The recovered isolates in vaccinated
herds were all identified as genotype 1A(I). Based on
the SmaI pattern, genotypes 1A(I) and 1(AII) appear
to be closely related, which means that the data from
this study are not definitely able to prove or disprove
whether reversion occurred. Attempts using other en-
zymes like XbaI and NotI for erysipelas digestion
failed to provide readable bands for differentiation of
isolates (data not shown). In this regard, future work
should focus on identifying other enzymes that will
allow detection of differences or confirm the similarity
between genotype 1A(I) isolates and vaccine strains.
The results of this study do not provide an expla-
nation for the reemergence of erysipelas cases in 2001.
The recent erysipelas outbreaks, as in the past, were
most likely due to failure to use vaccines. Two doses
of the killed bacterins are recommended for protective
immunity,1 and sometimes producers give only 1 dose.
A recent study showed that a single oral dose of at-
tenuated live vaccine provides immunity against swine
erysipelas for at least 18 weeks (Sick F, Hayes P: 2001,
Proc Leman Conf: 45). Efficacy of delivery of vaccine
to pigs via the water system may also be problematic.
Use of multiple antigen products has also been a con-
cern. One group recently compared the antibody titers
of gilts vaccinated with single-antigen erysipelas vac-
cines with those vaccinated with products containing
multiple antigens. They found that all vaccinated gilts
were protected against the disease; however, gilts vac-
cinated with single-antigen vaccines had significantly
higher titers than the gilts vaccinated with multiple-
antigen vaccines (Ritzmann M, Heinritzi P: 2001, Proc
Leman Conf: 43).
Another explanation for the outbreaks of erysipelas
in well-vaccinated herds may be improper vaccine
management (timing, proper storage, administration,
etc.). The vaccine may be administered at an age when
the pigs still have high maternal antibody titers that
interfere with development of active immunity. It is
also possible that concurrent infection with viruses
such as porcine reproductive and respiratory syndrome
virus (PRRSV), porcine circovirus type 2 (PCV2), or
other agents may suppress the immune response and
compromise development of protective immunity. A
trial with erysipelas vaccination and infection with
PRRSV recently demonstrated that pigs developed
erysipelas after immunization for E. rhusiopathiae and
challenge with PRRSV.7 More work on the effect of
viruses such as PRRSV and PCV2 on the safety and
efficacy of live erysipelas vaccines is warranted.
The PFGE described in this work will provide a
useful epidemiological tool to monitor future erysip-
elas outbreaks.
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